Correlation Between Codexis and Verve Therapeutics

Can any of the company-specific risk be diversified away by investing in both Codexis and Verve Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Codexis and Verve Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Codexis and Verve Therapeutics, you can compare the effects of market volatilities on Codexis and Verve Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Codexis with a short position of Verve Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Codexis and Verve Therapeutics.

Diversification Opportunities for Codexis and Verve Therapeutics

0.29

Correlation Coefficient

Codexis  Verve Therapeutics

Modest diversification

The 3 months correlation between Codexis and Verve is 0.29. Overlapping area represents the amount of risk that can be diversified away by holding Codexis and Verve Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Verve Therapeutics and Codexis is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Codexis are associated (or correlated) with Verve Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Verve Therapeutics has no effect on the direction of Codexis i.e., Codexis and Verve Therapeutics go up and down completely randomly.

Pair Corralation between Codexis and Verve Therapeutics

Given the investment horizon of 90 days Codexis is expected to under-perform the Verve Therapeutics. In addition to that, Codexis is 1.04 times more volatile than Verve Therapeutics. It trades about -0.11 of its total potential returns per unit of risk. Verve Therapeutics is currently generating about 0.01 per unit of volatility. If you would invest  554.00  in Verve Therapeutics on December 29, 2024 and sell it today you would lose (32.00) from holding Verve Therapeutics or give up 5.78% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Codexis  vs.  Verve Therapeutics

Codexis

Risk-Adjusted Performance

Very Weak

Over the last 90 days Codexis has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Verve Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Verve Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Verve Therapeutics is not utilizing all of its potentials. The newest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Pair Trading with Codexis and Verve Therapeutics

The main advantage of trading using opposite Codexis and Verve Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Codexis position performs unexpectedly, Verve Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Verve Therapeutics will offset losses from the drop in Verve Therapeutics' long position.

The idea behind Codexis and Verve Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.